UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1296-1304

2019

Volltextzugriff (PDF)

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Volltextzugriff (PDF)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet (British edition), 2019-01, Vol.393 (10167), p.156-167

2019

Volltextzugriff (PDF)

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Annals of oncology, 2018-05, Vol.29 (5), p.1235-1248

2018

Volltextzugriff (PDF)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Volltextzugriff (PDF)

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1468-1479

2018

Volltextzugriff (PDF)

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Journal of clinical oncology, 2022-09, Vol.40 (26), p.3065-3076

2022

Volltextzugriff (PDF)

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Clinical cancer research, 2022-05, Vol.28 (9), p.1792-1799

2022

Volltextzugriff (PDF)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1774-1784

2020

Volltextzugriff (PDF)

A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)

Annals of oncology, 2018-03, Vol.29 (3), p.731-736

2018

Volltextzugriff (PDF)

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of clinical oncology, 2020-06, Vol.38 (17), p.1875-1886

2020

Volltextzugriff (PDF)

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

Journal of clinical oncology, 2020-09, Vol.38 (26), p.3042-3050

2020

Volltextzugriff (PDF)

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Journal of clinical oncology, 2019-04, Vol.37 (10), p.799-808

2019

Volltextzugriff (PDF)

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Journal of clinical oncology, 2021-01, Vol.39 (3), p.190-201

2021

Volltextzugriff (PDF)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells

Cellular and molecular life sciences : CMLS, 2019-02, Vol.76 (4), p.681-697

2019

Volltextzugriff (PDF)

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer

Cochrane database of systematic reviews, 2019-02, Vol.2 (2), p.CD012873

2019

Volltextzugriff (PDF)

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Biochimica et biophysica acta. Reviews on cancer, 2021-01, Vol.1875 (1), p.188481, Article 188481

Rizzo, Milena

2021

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial

JAMA oncology, 2020-03, Vol.6 (3), p.e193692

2020

Volltextzugriff (PDF)

New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis

The Journal of urology, 2020-04, Vol.203 (4), p.751-759

2020

Volltextzugriff (PDF)

1 – 25 von 2.389

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.306)
Mit Volltextzugriff
(2.110)

Publikationsform

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(2.343)
Science & Technology
(2.155)
Life Sciences & Biomedicine
(2.130)
Docetaxel
(2.004)
Oncology
(1.730)
Middle Aged
(1.699)
Female
(1.660)
Aged
(1.557)
Male
(1.375)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(1.243)
Adult
(1.203)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1.091)
Taxoids - Administration & Dosage
(1.080)
Taxoids - Adverse Effects
(1.042)
Chemotherapy
(938)
Treatment Outcome
(866)
Biological And Medical Sciences
(787)
Medical Sciences
(787)
Breast Neoplasms - Drug Therapy
(570)
Tumors
(537)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.370)
Journals@Ovid Full Text
(1.094)
Ingenta
(1.090)
EZB Electronic Journals Library
(1.060)
IngentaConnect Journals
(571)
Springer Journals
(553)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(470)
Publisher or Other Site
(419)
Access via ScienceDirect (Elsevier)
(349)
Wiley-Blackwell Journals
(259)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(245)
Wiley Online Library
(184)
Access via Taylor & Francis
(120)
Taylor & Francis
(111)
Nature International Weekly Journal of Science
(103)
SpringerLink Series
(94)
Taylor & Francis Journals Complete
(80)
Oxford Journals
(62)
Nexis Uni
(53)
Oxford Journals 2020 Medicine
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(204)
Cancer Chemotherapy And Pharmacology
(168)
Anticancer Research
(98)
Cancer
(79)
British Journal Of Cancer
(77)
Lung Cancer
(58)
European Journal Of Cancer
(55)
Anti-Cancer Drugs
(52)
Investigational New Drugs
(50)
Supportive Care In Cancer
(45)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial

New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis

Suchergebnisse filtern